Navigation Links
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Date:12/6/2011

subcutaneous dispersion and absorption of these drugs. Molecules as large as 200 nanometers may pass freely through the extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin. The principal focus of Halozyme's Enhanze technology platform is the use of rHuPH20 to facilitate subcutaneous administration for large molecule biological therapeutics, some of which currently require intravenous administration.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States and at least 10,000 people in the European Union.

For more information on HAE, visit the HAEi's (International Patient Organization for C1 Inhibitor Deficiencies) website at www.haei.org and the U.S. HAE Association's website at: www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet med
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ViroPharma to Participate in Two November Healthcare Investor Conferences
2. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
3. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
4. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
5. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
6. ViroPharma Announces Additional Securities Repurchase Program
7. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
8. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
9. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
10. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... ORLANDO, Fla. , May 18, 2013 ... and are considered the most sensitive method for ... completely effective in preventing cancer cases 3 . EndoChoice ... its new Fuse™ system significantly improves the accuracy of ... missed by colonoscopists. EndoChoice will be discussing these clinical ...
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
(Date:5/18/2013)... , May 18, 2013 Faruqi & ... is investigating potential securities fraud at AVEO Pharmaceuticals, ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... its executives violated federal securities laws by issuing ... Phase III drug trials for Tivopath (tivozanib) (titled ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... safety data from VELOUR, the pivotal Phase III trial ... metastatic colorectal cancer (mCRC) will be presented by Edith ... Angiogenesis Foundation,s 9th Annual M. Judah Folkman International Conference: ... 2011 at the Hyatt Regency Cambridge. The ...
... Inc. (NYSE Amex: PIP ) today announced ... in the Delaware Court of Chancery. PharmAthene filed the ... in ST-246, an orally available smallpox antiviral drug candidate. ... decision," remarked Eric I. Richman, President and Chief Executive ...
Cached Medicine Technology:Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundation's 2011 M. Judah Folkman International Conference in Cambridge, Mass. 2PharmAthene Awarded 50% Profit Split on Worldwide Sales of Smallpox Antiviral Therapy by Delaware Chancery Court 2PharmAthene Awarded 50% Profit Split on Worldwide Sales of Smallpox Antiviral Therapy by Delaware Chancery Court 3
(Date:5/18/2013)... TheBeautyPlace.com answers important questions about the ... not a result of stress, nutrient deficiency or wearing ... 70% of men suffer from male patterned baldness. ... for hair transplant surgery, but additionally carries a hair ... as Bosley Professional Strength. Their product line is a ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... mount in courts throughout the country, Bernstein Liebhard LLP ... hip replacement patients often suffer tissue damage before they ... study, which according to Science Daily will appear in ... hip replacement recipients underwent MRI screens of their hips. ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Although obesity ... tumors, the association between obesity and esophageal adenocarcinoma, a ... other obesity-related tumors. As reported on Cancer.gov, ... are almost twice as likely as those of normal ... the relationship between obesity and esophageal cancer is not ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The “Sleep ... Pulse Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, ... Forecast to 2017” analyzes and studies the major market ... and Rest of the World. , Browse , ... 16 Figures , 318 ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Adolescents, especially ... known as “Spice” or “K2” are landing in emergency ... to curb this drug epidemic with a new ... marijuana. , According to research from the National Institute ... popular illegal drug among American teenagers. In 2012, 11 ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2
... initiatives designed to improve the management of rheumatoid arthritis ... the Annual Congress of the European League Against Rheumatism ... impact score , The first, a EULAR initiative entitled ... Impact of Disease, (RAID) score, was based on patients, ...
... Injury Is Key, WASHINGTON, June 13 ... will fly to Germany on Saturday,to work with ... in,assessing their current rehabilitation practices. They will also ... care given to,injured soldiers and other military personnel ...
... Rising Medical Solutions, Inc.,(Rising), a leading medical-financial ... have chosen Bank of America as their ... management offerings., (Logo: http://www.newscom.com/cgi-bin/prnh/20080206/AQW030LOGO-b ), ... America Direct(R) treasury,services as the foundation for ...
... knowledge of safety, privacy, emergency practices, but will leave them ... parents leave their tweens home alone for an extended period ... to 13-year-olds have the knowledge or skills to stay safe, ... C.S. Mott Children,s Hospital National Poll on Children,s Health ...
... EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-stage ... cancer and inflammatory diseases,announced today that James ... present a Company overview during the Business ... International Convention,being held June 17-20, 2008 at ...
... (PAH)chronically high blood pressure in the blood vessels of ... or HN) have a very poor chance of survival ... to new research from the University of Pennsylvania. ... advanced left heart failure but has never been demonstrated ...
Cached Medicine News:Health News:New insight into RA patient priorities and motivators for clinical trial involvement 2Health News:New insight into RA patient priorities and motivators for clinical trial involvement 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:Rising Medical Solutions Chooses Bank of America to Bring Enhanced Cash Management and Provider Payment Solutions to the Marketplace 2Health News:Rising Medical Solutions Chooses Bank of America to Bring Enhanced Cash Management and Provider Payment Solutions to the Marketplace 3Health News:Parents Worry About Tweens Left Alone 2Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:Serum sodium predicts mortality 10 times higher in PAH patients 2
HDL Cholesterol, liquid....
For the quantitative determination of high density lipoprotein (HDL) in human serum....
... Intended for the ... in plasma. Two vials, ... Enzymatic, alphaketoglutarate. Uses NADPH ... other plasma compounds. Reaction: ...
... The Proteomeworks system is an ... technologies that enables protein function ... sample preparation, 2-D electrophoresis, staining, ... excision, automated protein digestion, mass ...
Medicine Products: